13 M
Alternative Names: 13-MLatest Information Update: 23 Jun 2023
At a glance
- Originator University of Oslo
- Developer Cadila Pharmaceuticals; Serca Pharmaceuticals
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial infarction
Most Recent Events
- 22 May 2023 Preclinical trials in Myocardial infarction in Norway (Parenteral), prior to May 2023
- 22 May 2023 Preclinical trials in Myocardial infarction in Norway (PO), prior to May 2023
- 22 May 2023 Serca Pharmaceuticals announces intention to submit IND to the US FDA to for myocardial infarction in 2024